Statins could protect against motor neurone disease, scientists suggestHigh cholesterol could be a risk factor in development of motor neurone disease, according to a study of Share XStatins could protect against motor neurone disease, scientists suggesthttps://pharmaphorum.com/news/statins-could-protect-against-motor-neurone-disease-scientists-suggest/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
Alector kicks off biotech IPOs after US government shutdownThe 35-day US government shutdown has not just played havoc at government-run agencies – it has had a Share XAlector kicks off biotech IPOs after US government shutdownhttps://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/
Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
Roche’s SMA drug gets PRIME regulatory status in EuropeRoche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular Share XRoche’s SMA drug gets PRIME regulatory status in Europehttps://pharmaphorum.com/news/roches-sma-drug-gets-prime-regulatory-status-in-europe/
Lilly focuses on tau with AC Immune Alzheimer’s R&D tie-upEli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss Share XLilly focuses on tau with AC Immune Alzheimer’s R&D tie-uphttps://pharmaphorum.com/news/lilly-focuses-on-tau-with-ac-immune-alzheimers-rd-tie-up/
Neurocrine slumps as Tourette’s drug fails clinical trialShares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed Share XNeurocrine slumps as Tourette’s drug fails clinical trialhttps://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/
GW launches cannabis-based epilepsy drug in USGW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare Share XGW launches cannabis-based epilepsy drug in UShttps://pharmaphorum.com/news/gw-launches-cannabis-based-epilepsy-drug-in-us/
Akili gains rights to UCSF therapeutic video gameDigital health firm Akili has struck a deal with the University of California, giving it exclusive rights to Share XAkili gains rights to UCSF therapeutic video gamehttps://pharmaphorum.com/news/akili-gains-rights-to-ucsf-therapeutic-video-game/
